Replimune's Rollercoaster: From Double Rejection to FDA Panel Endorsement
Published on 08/04/2026 at 06:23 | Redaktion boerse-global.de
The biotech sector thrives on narrative reversals, and few have been as stark as Replimune's recent trajectory. After absorbing two regulatory rejections, the company has suddenly found itself on the winning side of a pivotal FDA advisory vote — a shift that has sent its share price into overdrive and reignited the bull case for its lead melanoma candidate.
A 10-3 Vote That Changes the Conversation
The turning point came when an FDA advisory committee voted 10 to 3 in favor of RP1, the company's modified herpes-virus therapy designed to treat advanced melanoma. The panel concluded that the treatment's benefits for severely ill patients outweigh its risks — a conclusion that carries significant weight even though the vote is non-binding.
The therapy, known scientifically as vusolimogene orparepvec, targets patients who have already undergone anti-PD-1 treatment. That specific patient population had previously failed to convince regulators, leading to rejection letters in July 2025 and April 2026. This third submission, however, benefited from priority review status granted due to the high unmet medical need.
The Data Behind the Endorsement
The advisory committee's positive stance draws on results from the IGNYTE study, which showed a median overall survival of 32.9 months. Roughly 34 percent of patients responded to the treatment, and nearly half of participants survived through the first three years following therapy initiation.
Should investors sell immediately? Or is it worth buying Replimune?
Those figures have emboldened analysts at BMO and Wedbush, both of whom maintain "Outperform" ratings on the stock. The survival data, in particular, forms the backbone of their bullish thesis.
A Rally That Outpaces Expectations
The market's reaction has been nothing short of explosive. The stock climbed 7.96 percent on Monday alone, closing at EUR 10.35, capping a seven-day surge of 120.39 percent. A separate snapshot shows the shares gaining roughly 39 percent over a single week to reach EUR 10.57 — a reminder that timing and measurement windows can paint slightly different pictures of the same momentum.
Yet the rally has created an uncomfortable gap. The average analyst price target sits at EUR 9.26, roughly 10 percent below the current trading level. In other words, the market is pricing in more optimism than the analyst community collectively endorses.
Not everyone is convinced. HC Wainwright maintains a sell recommendation, and the broader consensus remains stuck at "Hold." The regulatory path, despite the favorable vote, is far from a foregone conclusion.
Balancing Optimism Against Risk
Replimune's market capitalization now stands at approximately EUR 817 million, reflecting substantial expectations for eventual approval. The relative strength index of 60.1 suggests the stock is approaching overbought territory without having crossed that threshold — room to run, but little margin for disappointment.
Replimune at a turning point? This analysis reveals what investors need to know now.
The company's balance sheet offers some comfort: roughly USD 269 million in reserves should fund operations into 2027, providing ample runway to prepare for a commercial launch should approval materialize. Management is also slated to report quarterly earnings in August, which will arrive amid a dense calendar of FDA decisions across the biotech sector.
History suggests the FDA typically follows its advisory committees' recommendations. That pattern works in Replimune's favor. But the stock has already more than doubled in a matter of days, and any delay or unexpected nuance in the final decision would hit a share price that has little cushion left. The annual volatility of nearly 330 percent underscores just how frayed investor nerves remain beneath the surface of this rally.
For Replimune, the odds of finally securing approval look better than they ever have. The challenge now is whether the market's enthusiasm has gotten ahead of the outcome — and whether the stock can hold its gains through the final stretch of regulatory review.
Ad
Replimune Stock: New Analysis - 4 August
Fresh Replimune information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
